Vertex Pharmaceuticals News

's stock had its "overweight" rating restated by analysts at Barclays Capital in a research report issued to clients and investors on Friday.

May isn't in the books yet, but three health-care stocks have shot to the stratosphere.

's stock had its "overweight" rating restated by analysts at Barclays Capital in a research report issued to clients and investors on Friday.

CAMBRIDGE, Mass. -- -- Vertex Pharmaceuticals Incorporated today announced that Vertex will webcast its presentation at the Sanford C. Bernstein Strategic Decisions Conference on Wednesday, May 30, 2012 at 8:00 a.m. EDT and at the Goldman Sachs Global Healthcare Conference 2012 on Wednesday, June 6, 2012 at 1:20 p.m. PDT .

Vertex Receives European CHMP Positive Opinion for KALYDECOa , the First Medicine to Treat the Underlying Cause of Cystic Fibrosis CAMBRIDGE, Mass.

Vertex Pharmaceuticals Incorporated announced today that the European Committee for Medicinal Products for Human Use has issued a positive opinion by consensus recommending the approval of KALYDECO a for people with cystic fibrosis ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance ... (more)

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia CAMBRIDGE, Mass.-- --Vertex Pharmaceuticals Incorporated today announced that David Altshuler, M.D., Ph.D., joined its board of directors as an independent director.

Peter A. DiBiaso is the head of clinical business operations for Vertex Pharmaceuticals and responsible for the leadership of clinical business operations in support of Vertex's global development portfolio.

Titan International : "We had management on the show... they were optimistic. I share their optimism.

Drug approval decisions garner big headlines, but savvy and successful biotech investors know that making smart trading decisions ahead of important clinical trial results is the ticket to banking serious coin.

Boger stepped down three years ago as chief executive of Vertex Pharmaceuticals Inc., the company he founded in 1989 that now has a blockbuster hepatitis C drug and a new treatment for cystic fibrosis.

The company offers INCIVEK , approved for the treatment of patients with genotype 1 hepatitis C virus infection, and KALYDECO , approved for the treatment of patients with cystic fibrosis .

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia The Crohn's and Colitis Foundation of Canada and Vertex Pharmaceuticals Announce Collaboration to Fund Research in Inflammatory Bowel Disease TORONTO & LAVAL, Quebec-- ... (more)

Despite all the gloom and doom in the markets over the past 60 days the biotechnology sector has barely flinched and is currently at YTD highs.

With the biotech and pharmaceutical industries facing considerable challenges but also tremendous growth opportunities, attendees can expect to gain valuable insights into the future of biotech and big pharma.

I can't thank you all enough for all of your support with the Raymond James Boca Grande Classic and taking time out of your busy schedules to join us for this special event May 2-5. The tournament is truly a team effort and we could not have done it without each and every one of you.

The time has come for redefining the meaning of "creating shareholder value" in the biotech sector.

In trading on Monday, the Biotech ETF is outperforming other ETFs, up about 0.5% on the day.

HotStockProfits.com Releases New Technical Trading Reports on Francesca's Holdings Corp , InterOil Corporation and Vertex Pharmaceuticals Incorporated Hot Stock Profits, the leading online investment portal, has just released a new technical trading report on FRAN, IOC, and VRTX .To receive these reports, please sign-up to the FREE e-newsletter at ... (more)

NEW YORK &#8212 Vertex Pharmaceuticals Inc. shares rose Monday after a JPMorgan analyst upgraded the stock, forecasting greater sales for its cystic fibrosis drug Kalydeco and an experimental treatment called VX-809. THE SPARK: Analyst Geoff Meacham raised his rating to "Overweight" from "Neutral" and boosted his price target for the shares to $82 ... (more)